Temedica launches comprehensive digital companion “Dibi” for Type 2 Diabetes, sponsored by Novo Nordisk Pharma GmbH

New support for people with Type 2 Diabetes: Temedica introduces 'Dibi', sponsored by Novo Nordisk

• Innovative digital companion Dibi aims to simplify disease management for individuals with Type 2 diabetes.
• The app provides targeted support for insulin-naïve patients, guiding them through their journey into insulin therapy.
• Developed in close collaboration with patients, the app ensures tailored support and assistance.

Temedica has announced the launch of its groundbreaking digital companion, Dibi, designed for individuals with Type 2 diabetes. The app is sponsored by Novo Nordisk Pharma GmbH, Germany. Dibi offers comprehensive support across all stages of diabetes care, with a particular focus on insulin-naïve patients facing the challenges of starting insulin therapy.

The app represents a significant advancement in patient-centric care. By involving medical professionals and patients in the development process, Dibi has been tailored to meet the specific needs and experiences of individuals with Type 2 diabetes.

By connecting the digital companion to Temedica’s Real-World Evidence platform, Permea, app users receive regular, relevant insights derived from the latest research findings and the integration of diverse data and information sources. Additionally, users can contribute their patient experiences to scientific research, helping deepen the understanding of the real-world care landscape for Type 2 diabetes in Germany. This enables precise and personalized support while adhering to GDPR regulations and only with explicit patient consent.

Gloria Seibert

Founder & Chief Executive Officer at Temedica

“Our approach at Temedica is to place patients at the heart of our innovations. With ‘Dibi,’ we are setting a new standard for Type 2 diabetes care. By leveraging our expertise in Real-World Evidence, we aim to enhance the understanding and management of the disease while significantly improving the quality of life for those affected".

About Temedica

Temedica is a health insights company based in Munich. Since 2016, it operates Europe's leading ecosystem for real-world insights in the healthcare sector. Temedica's mission is to enable personalized and individualized medicine, thereby focusing on patients and their individual needs. The company achieves this by linking health-related data from various sources, which are processed into valuable insights in compliance with the GDPR.

Temedica is backed by a consortium of renowned investors with many years of experience in the biopharmaceutical industry, including the founding investors of BioNTech. For further information, please visit www.temedica.com.

About Novo Nordisk Germany

Novo Nordisk is a global healthcare leader founded in 1923 and headquartered in Denmark. Novo Nordisk is dedicated to driving change with the goal of defeating serious chronic diseases, leveraging its extensive expertise in diabetes care.

The company works on scientific innovations aimed at curing diseases, expanding access to its products for patients worldwide, and actively promoting prevention. Novo Nordisk employs approximately 66,000 people in 80 countries and markets its products in about 170 countries. In Germany, around 500 employees work for Novo Nordisk, with approximately half based at its headquarters in Mainz. For more information, visit www.novonordisk.de.

For further information and media inquiries, please contact:

Temedica GmbH

Anna Hauner

Corporate Communications

E-Mail: pr@temedica.com

T: + 49 175 431 030 1

Discover more about Dibi and its features at www.dibi-app.de.